![Quiver Logo](/static/img/logo-icon.png)
![BCTXW logo](https://quiver-logos.s3.us-east-2.amazonaws.com/bctxw.png)
BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BCTXW Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of BCTXW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BCTXW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to BCTXW
Recent picks made for BCTXW stock on CNBC
ETFs with the largest estimated holdings in BCTXW
Flights by private jets registered to BCTXW
![Quiver Logo](/static/img/logo-icon.png)